Net Worth Advisory Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Net Worth Advisory Group’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-388	Closed	-$203K	–	446
2026 Q1	$203K	Buy	+388	New	+$185K	0.04%	413

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Net Worth Advisory Group's MDGL Position: Q2 2026 in Review

Net Worth Advisory Group sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 388 shares — an estimated $203K sold.

Net Worth Advisory Group first reported a position in MDGL in Q1 2026 and held it in 1 quarter. The position peaked at $203K in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Net Worth Advisory Group reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Net Worth Advisory Group sold 388 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $203K.
Net Worth Advisory Group first reported a position in Madrigal Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Net Worth Advisory Group's Madrigal Pharmaceuticals position peaked at $203K in Q1 2026.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Net Worth Advisory Group's 13F filing for Q2 2026, filed 14 Jul 2026.